Variation in ACE activity affects myogenic differentiation in C2C12 cells

Biochemical and Biophysical Research Communications

Volumn 353, Issue 2, 2007, Pages 369-375

  Mori, Shuuichi ^a   Tokuyama, Kumpei ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

ACE; Angiotensin II; AT2 receptor; C2C12; Captopril; Differentiation; Myogenesis

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; MYOSIN HEAVY CHAIN;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL POPULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; MOUSE; MUSCLE DEVELOPMENT; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; UPREGULATION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; ENZYME ACTIVATION; MICE; MUSCLE DEVELOPMENT; MYOBLASTS; PEPTIDYL-DIPEPTIDASE A;

EID: 33845882497     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.12.056     Document Type: Article

References (26)

1. Corvol P., Williams T.A., and Soubrier F. Peptidyl dipeptidase A: angiotensin I-converting enzyme. Methods Enzymol. 248 (1995) 283-305
2. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J. Am. Coll. Cardiol. 20 (1992) 248-254
3. Vescovo G., Libera L.D., Serafini F., Leprotti C., Facchin L., Volterrani M., Ceconi C., and Ambrosio G.B. Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. Circulation 98 (1998) 1742-1749
4. Onder G., Phenninx B.W., Balkrisshnan R., Fried L.P., Chaves P.H.M., Williamson J.D., Carter C., Di Bari M., Guralnik J.M., and Pahor M. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet 359 (2002) 926-930
5. Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., and Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86 (1990) 1343-1346
6. Danser A.H., Schalekamp M.A., Bax W.A., van den Brink A.M., Saxena P.R., Riegger G.A., and Schunkert H. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 92 (1995) 1387-1388
7. Costerousse O., Allegrini J., Lopez M., and Alhenc-Gelas F. Angiotensin-I converting enzyme in human circulating mononuclear cells: Genetic polymorphism of expression in T-lymphocytes. Biochem. J. 290 (1993) 33-40
8. Montogomery H.E., Marshall R.M., Hemingway H., Myerson S., Clarkson P., Dollery C., Hayward M., Holliman D.E., Jubb M., World M., Tomas E.L., Brynes A.E., Saeed N., Barnard M., Bell J.D., Prasad K., Rayson M., Talmud P.J., and Humphries S.E. Human gene for physical performance. Nature 393 (1998) 221-222
9. Gayagay G., Yu B., Hambly B., Boston T., Hahn A., Celermajer D.S., and Trent R.J. Elite endurance athletes and the ACE I allele-the role of genes in athletic performance. Hum. Genet. 103 (1998) 48-50
10. Myerson S., Hemingway H., Budget R., Martin J., Humphries S., and Montgomery H. Human angiotensin I-converting enzyme gene and endurance performance. J. Appl. Physiol. 87 (1999) 1313-1316
11. Nazarov I.B., Woods D.R., Montgomery H.E., Shneider O.V., Kazarov V.I., Tomilin N.V., and Rogozkin V.A. The angiotensin converting enzyme I/D polymorpshim in Russian athletes. Eur. J. Hum. Genet. 9 (2001) 797-801
12. Jones A., and Woods D.R. Skeletal muscle RAS and exercise performance. Int. J. Biochem. Cell Biol. 35 (2003) 855-866
13. Hawke T.J., and Garry D.J. Myogenic satellite cells: physiology to molecular biology. J. Appl. Physiol. 91 (2001) 534-551
14. Friedland J., and Silverstein E. A sensitive fluorimetric assay for serum angiotensin-converting enzyme. Am. J. Clin. Pathol. 66 (1976) 416-424
15. Suzuki A., Obi K., Urabe T., Hayakawa H., Yamada M., Kaneko S., Onodera M., Mizuno Y., and Mochizuki H. Feasibility of ex vivo gene therapy for neurological disorders using the new retroviral vector GCDNsap packaged in the vesicular stomatitis virus G protein. J. Neurochem. 82 (2002) 953-960
16. Sanders P.M., Russell S.T., and Tisdale M.J. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br. J. Cancer 93 (2005) 425-434
17. Reneland R., and Lithell H. Angiotensin-converting enzyme in human skeletal muscle. A simple in vitro assay of activity in needle biopsy specimens. Scand. J. Clin. Lab. Invest. 54 (1994) 105-111
18. Dragovic T., Minhall R., Jackman H.L., Wang L.-X., and Erdos E.G. Kininase II-type enzymes. Their putative role in muscle energy metabolism. Diabetes. Suppl. 1 (1996) S34-S37
19. Cai D., Lee K.K.H., Li M., Tang M.K., and Chan K.M. Ubiquitin expression is up-regulated in human and rat skeletal muscles during aging. Arch. Biochem. Biophys. 425 (2004) 42-50
20. Rankinen T., Wolfarth B., Simoneau J., Maier-Lenz D., Rauramaa R., Rivera M.A., Boulay M.R., Chagnon Y.C., Perusse L., Keul J., and Bouchard C. No association between the angiotensin-converting enzyme ID polymorphism and elite endurance athlete status. J. Appl. Physiol. 91 (2000) 1571-1575
21. Williams A.G., Day S.H., Folland J.P., Gohlke P., Dhamrait S., and Montgomery H.E. Circulating angiotensin converting enzyme activity is correlated with muscle strength. Med. Sci. Sports Exerc. 37 (2005) 944-948
22. Gordon S.E., Davis B.S., Carlson C.J., and Booth F.W. ANG II is required for optimal overload-induced skeletal muscle hypertrophy. Am. J. Physiol. Endocrinol. Metab. 280 (2001) E150-E159
23. McBride T.A. AT1 receptor are necessary for eccentric training-induced hypertrophy and strength gains in rat skeletal muscle. Exp. Physiol. 91 (2006) 413-421
24. Horiuchi M. Angiotensin II receptor. Nippon Rinsho 62 (2004) 29-36
25. Linderman J., Greene A.S., and muscle D.o.a.I.r.e.i.t.m.o.s. Microcirculation 8 (2001) 275-281
26. Matsubara H. Pathophysiological role of angiotensin type 2 receptor in cardiovascular and renal disease. Circ. Res. 83 (1998) 1182-1191